-
1 Comment
North China Pharmaceutical Company Ltd is currently in a long term downtrend where the price is trading 1.0% below its 200 day moving average.
From a valuation standpoint, the stock is 86.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
North China Pharmaceutical Company Ltd's total revenue rose by 12.0% to $3B since the same quarter in the previous year.
Its net income has increased by 54.1% to $19M since the same quarter in the previous year.
Finally, its free cash flow grew by 28.2% to $58M since the same quarter in the previous year.
Based on the above factors, North China Pharmaceutical Company Ltd gets an overall score of 4/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE000000D16 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.63 |
|---|---|
| Market Cap | 10B |
| PE Ratio | 60.8 |
| Target Price | 12.39 |
| Dividend Yield | None |
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China. The company primarily offers anti-infective drugs; biotechnology drugs; cardiovascular cerebrovascular; immunomodulators; and vitamins and health products. It also provides chemical pharmaceuticals, biological agricultural and veterinary drugs. North China Pharmaceutical Company.Ltd was founded in 1992 and is based in Shijiazhuang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600812.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
